This article is more than 5 years old. Information may no longer be current.

FDA approves treatment for meibomian gland dysfunction

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

MORRISVILLE, N.C. — TearScience has received approval from the U.S. Food and Drug Administration to market a thermal pulsation system used to treat meibomian gland dysfunction, the company announced in a press release.

The LipiFlow Thermal Pulsation System is a 12-minute in-office treatment that applies directed energy to a patient's eyelid to remove meibomian gland obstructions.

The device will have limited availability in the U.S. through the end of 2011, according to the release.

TearScience will sell the LipiFlow and the LipiView Ocular Surface Interferometer as a system, which will enable physicians to assess tear film and meibomian gland function before conducting treatment, the release said.